Simultaneous sessions Sunday June 18

SIMULTANEOUS SESSION

08:00 - 09:15, Auditorium

ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES - CLINICAL
Chairs: K. Döhner (University of Ulm, Ulm, Germany) M. Sanz (Hospital Universitario La Fe, Valencia, Spain)

08:00 - 08:15 0975 CYTOGENETICS AND AGE ARE THE MAIN DETERMINANTS OF OUTCOME IN INTENSIVELY TREATED ACUTE MYELOID LEUKEMIA PATIENTS OLDER THAN 60 YEARS: RESULTS FROM AMLSG TRIAL AML HD98-B
R.F. Schlenk, S. Kayser, M. Morhardt, K. Döhner, H. Döhner, S. Fröhling (University of Ulm, Ulm, Germany) 08:15 - 08:30 0976 5-AZACITIDINE INDUCES REMISSIONS IN PATIENTS WITH TRANSFUSION DEPENDENT MYELOPROLIFERATIVE DISEASES AND IN PATIENTS WITH ACUTE MYELOID LEUKEMIA REFRACTORY TO OR NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY
H.K. Al-Ali, S. Schwind, C. Becker, C. Christl, D. Niederwieser (University of Leipzig, Leipzig, Germany) 08:30 - 08:45 0977 PHASE IB STUDY OF PKC412, AN ORAL FLT3 KINASE INHIBITOR, IN SEQUENTIAL AND SIMULTANEOUS COMBINATIONS WITH DAUNORUBICIN AND CYTARABINE (DA) INDUCTION AND HIGHDOSE CYTARABINE CONSOLIDATION IN NEWLY DIAGNOSED PATIENTS WITH AML
T. Fischer, F. Giles, R. Paquette, G. Schiller, G. Ehninger, C. Schiffer, J. Cortes, H. Kantarjian, D. DeAngelo, F. Heidel, P.S. Cohen, R. Yu, S. Bilic, L. Zhang, P.S. Phillips, R.M. Stone (University Hospital Mainz, Mainz, Germany) 08:45 - 09:00 0978 ARSENIC TRIOXIDE (ATO) IS SAFE AND EFFECTIVE IN COMBINATION WITH LOW-DOSE ARA-C (LDAC) FOR THE TREATMENT OF ADVANCED MYELODYSPLASTIC SYNDROME (MDS) AND POOR-PROGNOSIS ACUTE MYELOID LEUKEMIA (AML) IN ELDERLY PATIENTS
G.J.R. Roboz, E. Ritchie, S. Allen-Bard, T. Curcio, J. Provenzano, M. Samuel, M. Schuster, A. Bloch, E.J.F. Feldman (Weill Medical College of Cornell University New York, Ny, USA) 09:00 - 09:15 0979 CYTOGENETIC RESPONSES TO THE HYPOMETHYLATING AGENT, DECITABINE (DAC), IN A PHASE III TRIAL OF DAC VS SUPPORTIVE CARE (SC) IN PATIENTS (PTS) WITH MYELODYSPLASTIC SYNDROMES (MDS)

SIMULTANEOUS SESSION

08:00 - 09:15, Forum

ACUTE LYMPHOBLASTIC LEUKEMIA
Chairs: J.M. Ribera (Hospital Universitari Germans Trias i Pujol, Badalona, Spain) J. Holowiecki (Silesion Medical University, Katowice, Poland)

08:00 - 08:150980SINGLE NUCLEOTIDE POLYMORPHISMS OF THE MTHFR (C677T), MTRR (A66G) AND VITAMIN D RECEPTOR (CDX-2/GATA) GENES ARE IMPORTANT DETERMINANTS OF OSTEOPOROSIS IN PEDIATRIC ALL PATIENTS
R.D. van Beek, M.M. van der Heuvel, R. de Jonge, A.G. Uitterlinden, R. Pieters, S.M.P.F. de Muinck Keizer-Schrama (Erasmus Medical Center-Sophia, Rotterdam, The Netherlands) 08:15 - 08:30 0981 LATE RELAPSES IN T-ALL PATIENTS - TRUE DISEASE RECURRENCE OR SECOND T-ALL?
T. Szczepanski, V.H.J. van der Velden, B. Gruhn, R. Panzer-Grümayer, M. Spinelli, H. Cavé, D. Campana, A. Schrauder, E. van Wering, J.J.M. van Dongen (Silesian Academy of Medicine, Zabrze, Poland) 08:30 - 08:45 0982 RITUXIMAB AS A SINGLE AGENT DISPLAYS POTENT ACTIVITY AGAINST PRIMARY HUMAN CD20+ ACUTE LYMPHOBLASTIC LEUKEMIA IN A PRECLINICAL XENOGRAFTMODEL
B.A. Nijmeijer, M.L.J. van Schie, R. Willemze, J.H.F. Falkenburg (Leiden University Medical Center, Leiden, The Netherlands) 08:45 - 09:00 0983 ETV6/RUNX1 DIRECTLY DYSREGULATES GENES WITH RUNX1 BINDING SITE VIA MECHANISM REVERSIBLE BY HISTONE DEACETYLASE INHIBITORS
J. Starkova, J. Madzo, M. Zaliova, G. Cario, A. Ford, O. Hrusak, J. Trka (Childhood Leukaemia Investigation Prague, Prague, Czech Republic) 09:00 - 09:15 0984 MINIMAL RESIDUAL DISEASE STATUS IS THE MOST IMPORTANT PREDICTIVE FACTOR IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA. PALG 4-2002 PROSPECTIVE ALL-MRD STUDY
J. Holowiecki, M. Krawczyk-Kulis, S. Giebel, K. Jagoda, B. Stella-Holowiecka, B. Jakubas, M. Paluszewska, I. Seferynska, A. Czyz, G. Palynyczko, K. Nowak, W. Baran, A. Skotnicki, W.W. Jedrzejczak, K. Warzocha, A. Hellmann (Silesian Medical University, Katowice, Poland)

SIMULTANEOUS SESSION

08:00 - 09:15, Room B

HODGKIN'S LYMPHOMA - CLINICAL TRIALS
Chairs: M. Björkholm (Karolinska Institute, Stockholm, Sweden) J. Raemakers (Radboud University Medical Center, Nijmegen, The Netherlands)

08:00 - 08:15 0985 RECENT INTERIM ANALYSIS OF THE HD11 TRIAL OF THE GHSG: INTENSIFICATION OF CHEMOTHERAPY AND REDUCTION OF RADIATION DOSE IN EARLY UNFAVORABLE STAGE HODGKIN'S LYMPHOMA
A. Engert, V. Diehl, C. Brillant, A. Engert, R.P. Mueller, H.T. Eich, K. Mueller-Hermelink, R. Herrmann, J. Markova, H. Ho, W. Hiddemann, B. Doerken, R. Greil, A. Josting, B. Pfistner (University Hospital of Cologne, Köln, Germany) 08:15 - 08:30 0986 COMBINED MODALITY TREATMENT OF TWO OR FOUR CYCLES OF ABVD FOLLOWED BY INVOLVED FIELD RADIOTHERAPY IN THE TREATMENT OF PATIENTS WITH EARLY STAGE HODGKIN'S LYMPHOMA: UPDATE INTERIM ANALYSIS OF THE RANDOMISED HD10 STUDY OF THE GERMAN HODGKIN STUDY GROUP (GHSG
A. Engert, A. Pluetschow, H.T. Eich, R. Herrmann, B. Doerken, L. Kanz, R. Greil, J. Markova, B. Pfistner, A. Josting, K. Mueller-Hermelink, R.P. Mueller, V. Diehl (University Hospital of Cologne, Köln, Germany) 08:30 - 08:45 0987 PREDICTIVE VALUE ON TREATMENT OUTCOME OF EARLY [18F]-FDG PET SCAN IN ADVANCED STAGE HODGKIN'S DISEASE TREATED BY CONVENTIONAL CHEMOTHERAPY IS SUPERIOR TO IPS SCORE
A. Gallamini (Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy) 08:45 - 09:00 0988 AMH AND INHIBIN B ARE VALUABLE NEW MARKERS FOR GONADAL DAMAGE AFTER THE TREATMENT OF M. HODGKIN WITHOUT RADIOTHERAPY
R.D. van Beek, S.M.P.F. de Muinck Keizer-Schrama, R. Weber, J.S.E. Laven, F.H. de Jong, F.G. Hakvoort-Cammel, C. van der Bos, R. Pieters, M.M. van der Heuvel (Erasmus Medical Center-Sophia, Rotterdam, The Netherlands) 08:15 - 08:30 0989 THE POLYMORPHISM IN THE INTERLEUKIN-10 GENE PROMOTER AT -592 IS A PROGNOSTIC MARKER IN HODGKIN'S LYMPHOMA
S. Hohaus, M. Giachelia, A. Di Febo, M. Martini, G. Massini, B. Vannata, G. Mansueto, S. Piano, F. Guidi, F. D'Alo', L.M. Larocca, M.T. Voso, G. Leone (Universita' Cattolica S. Cuore, Rome, Italy)

SIMULTANEOUS SESSION

08:00 - 09:15, Room C

CELL SIGNALLING, TRANSCRIPTIONAL CONTROL AND APOPTOSIS - II
S. Constantinescu (Ludwig Institute for Cancer Research, Brussels, Belgium) K.M. Debatin (University Children's Hospital, Ulm, Germany)

08:00 - 08:15 0990 CD95L EXPRESSING ANTIGEN-PRESENTING CELLS PREVENT ANTIGEN-SPECIFIC T CELL RESPONSE BY APOPTOSIS INDUCTION AND INHIBITION OF T CELL ACTIVATION
G. Strauss, H. Kasperczyk, S. Fulda, K.M. Debatin (University Children's Hospital, Ulm, Germany) 08:15 - 08:30 0991 THE PROTO-ONCOGENE EVI1 INDUCES FETAL ANEMIA IN A CONDITIONAL TRANSGENIC MOUSE MODEL
H.C.M. van den Akker, D. Spensberger, K. van Lom, A. van Hoven-Beijen, C. Erpelinck, R. Ferreira, U. Klingmüller, J.N.J. Philipsen, R. Delwel (Erasmus Medical Center, Rotterdam, The Netherlands) 08:30 - 08:45 0992 ROLE OF LYMPHOID MICROENVIRONMENT IN INHIBITION OF APOPTOSIS AND ACTIVATION OF PI3-K/AKT PATHWAY AND PTEN IN B-CLL CELLS
M. Shehata, S. Schnabl, D. Demirtas, J. Schwarzmeier, M. Hilgarth, R. Hubmann, M. Duechler, A. Gaiger, U. Jaeger (Medical University of Vienna, Vienna, Austria) 08:45 - 09:00 0993 ANALYSIS OF APOPTOSIS SIGNALING IN PRIMARY LEUKEMIA CELLS AND ITS IMPACT ON TREATMENT RESPONSE AND LONG TERM SURVIVAL
K. Stahnke, L.H. Meyer, S.M. Eckhoff, K.M. Debatin (University Childrens Hospital, Ulm, Germany) 09:00 - 09:15 0994 VEGF REGULATES LEUKEMIA MIGRATION VIA FLT-1, INVOLVING PI3 KINASE, RHOA AND RAC1 ACTIVATION AND LIPID RAFTS/CAVEOLAE FORMATION
R. Fragoso, C. Casalou, S. Dias (Portuguese institute of Oncology, Lisboa, Portugal)

SIMULTANEOUS SESSION

08:00 - 09:15, Room L

ANEMIA / RED BLOOD CELLS
Chair: K. Lechner (Medical University Vienna, Vienna, Austria) W.W. van Solinge (University Medical Center Utrecht, Utrecht, The Netherlands)

08:00 - 08:15 0995 COLD SHOCK DOMAIN PROTEIN A (CSDA) ACTS AS REPRESSOR FACTOR OF GAMMA GLOBIN GENE EXPRESSION IN VIVO
M.G. Grosso (University of Naples Federico II, Napoli, Italy) 08:15 - 08:30 0996 ADJUVANT INTRAVENOUS IRON THERAPY POTENTIATES EPOETIN BETA TREATMENT IN ANEMIC, NON IRON-DEPLETED PATIENTS WITH LYMPHOPROLIFERATIVE DISORDERS: RESULTS OF THE NIFE STUDY
M. Hedenus, G. Birgegård, P. Näsman, L. Ahlberg, T. Karlsson, B. Lauri, J. Lundin, G. Lärfars, A. Österborg (Sundsvall Hospital, Sundsvall, Sweden) 08:30 - 08:45 0997 A NOVEL C TO G MUTATION IN THE HIF PROLYL HYDROXYLASE, PHD2, ASSOCIATED WITH ERYTHROCYTOSIS IN THREE FAMILY MEMBERS
M.J. Percy, Q. Zhao, A. Flores, C. Harrison, T.R.J. Lappin, P.H. Maxwell, M.F. McMullin, F.S. Lee (Belfast City Hosptial, Belfast, United Kingdom) 08:45 - 09:00 0998 SELECTED IMIDS(R) IMMUNOMODULATORY DRUGS: NEW APPROACHES TO THE REGULATION OF ERYTHROPOIESIS AND HEMOGLOBIN SYNTHESIS IN ß-HEMOGLOBINOPATHIES
A. Moutouh de Parseval, D. Verhelle, H. Brady, E. Glezer, N. Richard, U. Jhaveri, K. Jensen-Pergakes, L. Corral, C.L. Morris, G. Muller, K. Chan (Celgene, San Diego, USA) 09:00 - 09:15 0999 RESPONSE OF MYOCARDIAL T2* TO ORAL DEFERASIROX MONOTHERAPY FOR 1 YEAR IN 29 PATIENTS WITH TRANSFUSIONDEPENDENT ANAEMIAS; A SUBGROUP ANALYSIS
P. Eleftheriou, M. Tanner, D. Pennel, J.B. Porter (University College Hospital, London, United Kingdom)

SIMULTANEOUS SESSION

08:00 - 09:15, Room X

NON-HODGKIN'S LYMPHOMA / CHRONIC LYMPHOCYTIC LEUKEMIA - EXPERIMENTAL
Chairs: A. Rosenwald (University of Würzburg, Würzburg, Germany) G. Salles (Centre Hospitalier Lyon-Sud, Lyon, France)

08:00 - 08:15 1000 NOTCH-MEDIATED ACTIVATION OF PI-3K IS NEEDED FOR LYMPHOMAGENESIS IN T CELL-SPECIFIC PTEN-/- MICE
T.J. Hagenbeek, M. Naspetti, H. Spits (Academic Medical Center, Amsterdam, The Netherlands) 08:15 - 08:30 1001 ALLELIC SILENCING AT 13Q14.3: A NOVEL ONCOGENIC MECHANISM
D.M. Mertens, S. Wolf, C. Mund, D. Kienle, S. Ohl, P. Schroeter, F. Lyko, H. Döhner, S. Stilgenbauer, P. Lichter (DKFZ, Heidelberg, Germany) 08:30 - 08:45 1002 DYNAMIC MODIFICATIONS OF THE SURFACE B-CELL RECEPTOR LIGHT CHAIN IN CASES OF HAIRY CELL LEUKAEMIA OCCURRING AT EXTRAFOLLICULAR SITES
F. Forconi, T. Amato, D. Raspadori, S.S. Sahota, M.A. Dell'Aversano, M. Tassi, M. Defina, D. Rossi, L. Rigacci, F. Zaja, F. Gherlinzoni, S. Tavera, L. Leoncini, G. Gaidano, F.K. Stevenson, F. Lauria (Ematologia e Trapianti, Siena, Italy) 08:45 - 09:00 1003 REDIRECTION OF CMV SPECIFIC CTL TOWARDS B-CLL VIA CD20 TARGETED HLA/CMV COMPLEXES
R. Mous, P. Savage, E.B.M Remmerswaal, R.A.W. van Lier, E. Eldering, M.H.J. van Oers (Academic Medical Center, Amsterdam, The Netherlands) 09:00 - 09:15 1004 THE CYCLIN-DEPENDENT KINASE INHIBITOR SELICICLIB ENGAGES THE MITOCHONDRIAL APOPTOSIS PATHWAY VIA THE MCL-1/NOXA AXIS IN B-CLL
Y.H. Hallaert, R. Spijker, M. Jak, A. Jaspers, I.A.M. Derks, N.L. Alves, J.P. de Boer, D. de Jong, S.R. Green, R.A.W. van Lier, M.H.J. van Oers, E. Eldering (Academic Medical Center, Amsterdam, The Netherlands)

SIMULTANEOUS SESSION

10:30 - 11:45, Room L

PHARMACOGENETICS AND MOLECULAR TARGETING
Chairs: P. Valk (Erasmus Medical Center, Rotterdam, The Netherlands) P. Huijgens (VU University Medical Center, Amsterdam, The Netherlands)

10:30 - 10:451005 PHARMACOGENETIC ANALYSIS OF POLYMORPHISMS IN CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 AND MDR1 GENES FOR SURVIVAL AND THERAPY RELATED TOXICITY IN MULTIPLE MYELOMA
A. Broyl, C. Schilthuizen, B. van der Holt, Y. de Knegt, R.H.N. van Schaik, R.A. Raymakers, H.M. Lokhorst, E. Vellenga, E. Kamst, P. Sonneveld (Erasmus Medical Center, Rotterdam, The Netherlands) 10:45 - 11:001006 EXPOSURE OF LEUKEMIC CELLS TO ANTHRACYCLINES INDUCES RAPID AND BROAD UPREGULATION OF ATP BINDING CASSETTE TRANSPORTERS
P.L.M. de Grouw, A. Buda, A. van der Reijden, J. de Witte, H. Jansen, A.P. Raymakers, H.G.P. Raaijmakers (Radboud University Medical Centre, Nijmegen, The Netherlands) 11:00 - 11:151007 TARGETED INACTIVATION OF GERANYLGERANYLTRANSFERASE TYPE I RESCUES MICE FROM LETHALITY INDUCED BY ONCOGENIC K-RAS EXPRESSION IN GRANULOCYTES AND MONOCYTES
O. Bergo, A.K. Sjogren, K.A. Andersson, A.S. Svensson, M.L. Liu, B.C. Cutts, C.K. Karlsson, M.D. Dalin, S.G. Young (Institute of Medicine, Göteborg, Sweden) 11:15 - 11:301008 FLT3 MUTATED PEDIATRIC ACUTE MYELOID LEUKEMIA (AML) SAMPLES ARE SENSITIVE TO THE TYROSINE KINASE INHIBITOR SU11657
B.F. Goemans, C.H. Zwaan, D. de Lange, J. Cloos, Q. Waisfisz, D. Reinhardt, K. Hahlen, B.E. Gibson, U. Creutzig, G.J.L Kaspers (VU University Medical Center, Amsterdam, The Netherlands) 11:30 - 11:451009 DEVELOPMENT OF AN EFFECTIVE SAFETY SWITCH FOR SELECTIVE ELIMINATION OF HUMAN T CELLS IN VIVO AFTER ADOPTIVE TRANSFER
T. van Meerten, H. Rozemuller, W. Mackus, P. Parren, J. van de Winkel, M.-J. Claessen, R.S. van Rijn, A. Hagenbeek, A. Martens, S. Ebeling (University Medical Center Utrecht, Utrecht, The Netherlands)

SIMULTANEOUS SESSION

10:30 - 11:45, Room C

CANCER GENETICS AND CYTOGENETICS IN LYMPHOID DISEASES
Chairs: C.H. Geisler (Rigshospitalet, Copenhagen, Denmark) F. Speleman (University Hospital of Gent, Gent, Belgium)

10:30 - 10:451010 MOLECULAR KARYOTYPING BY HIGH RESOLUTION ARRAY CGH UNCOVERS AMPLIFICATIONS AND HOMOZYGOUS DELETIONS IN CD138 + SELECTED PRIMARY MULTIPLE MYELOMA CASES
C. Largo, B. Saez, J. Suela, B. Ferreira, S. Alvarez, D. Blesa, F. Prosper, M.J. Calasanz, J.C. Cigudosa (CNIO, Madrid, Spain) 10:45 - 11:001011 MOLECULAR ANALYSIS OF PATIENTS WITH T-ALL USING ARRAY-CGH ENRICHED IN PROBES COVERING TYROSINE KINASE GENES
I. Lahortiga, C. Graux, K. van Roosbroeck, N. Mentens, K. de Keersmaecker, F. Lambert, P. Vandenbergue, I. Wlodarska, G . Froyen, M.D. Maria, P. Marynen, J. Cools (VIB4, Leuven, Belgium) 11:00 - 11:151012 GENE EXPRESSION PROFILING OF APOPTOSIS GENES IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
M.L. Den Boer, A. Holleman, R.X. Menezes, M.H. Cheok, G.E. Janka-Schaub, W.E. Evans, R. Pieters (Erasmus Medical Center- Sophia Children's Hospital, Rotterdam, The Netherlands) 11:15 - 11:301013 CYCLIN D2 DYSREGULATION BY CHROMOSOMAL TRANSLOCATIONS TO TCR LOCI IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIAS
E. Clappier, W. Cuccuini, J.M. Cayuela, D. Vecchione, A. Baruchel, H. Dombret, F. Sigaux, J. Soulier (Hôpital Saint-Louis, Paris, France) 11:30 - 11:451014 DELINEATION OF CHROMOSOMAL CONSENSUS REGIONS IN MANTLE CELL LYMPHOMA USING A HIGH RESOLUTION GENOMIC MICROARRAY
H. Kohlhammer, S. Wessendorf, D. Kienle, H.A. Kestler, T.F.E. Barth, P. Möller, G. Ott, M. Bentz, P. Lichter, H. Döhner, S. Stilgenbauer, C. Schwänen (Universitätsklinikum Ulm, Ulm, Germany)

SIMULTANEOUS SESSION

10:30 - 11:45, Room X

ALLOGENEIC STEM CELL TRANSPLANTATION - CLINICAL
Chairs: W. Arcese (University of Rome, Rome, Italy) F. Dazzi (Imperial College, London, United Kingdom)
10:30 - 10:45 1015 LOW TREATMENT-RELATED MORTALITY AND RAPID REGRESSION OF BONE MARROW FIBROSIS AFTER REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MYELOFIBROSIS-AN INTERIM ANALYSES OF A PROSPECTIVE STUDY OF THE CHRONIC LEUKEMIA WORKING PARTY OF THE EUROPEAN GROUP OF BLOOD AND MARROW TRANSPLANTATION
N. Kröger, G. Kobbe, E. Holler, M. Bornhäuser, R. Schwerdtfeger, A. Nagler, W. Bethge, H. Wandt, P. Corradini, M. Stelljes, J. Thiele, L. Uharek, J. Schubert, A. Zander, D. Niederwieser, T. de Witte (University Hospital Hamburg, Hamburg, Germany) 10:45 - 11:00 1016 HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITHOUT IN VITRO T CELL DEPLETION FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES
X. Huang, D.H. Liu, K.Y. Liu, H. Chen, W. Han, Y.H. Chen, J.Z. Wang, Z.Y. Goa, Y.C. Zhang, Q. Jiang, H.X. Shi, D.P. Lu (Peking University Institute of Hematolog, Beijing, China) 11:00 - 11:15 1017 PURIFIED T DEPLETED PERIPHERAL BLOOD AND BONE MARROW CD34 TRANSPLANTATION FROM HAPLOIDENTICAL MOTHER TO CHILD WITH THALASSEMIA
B. Erer, P. Sodani, A. Isgrò, J. Gaziev, P. Polchi, A. Roveda, F. Pagliai, M. Andreani, L. Faulkner, V. Tintori, G. Adorno, A. Lanti, G. Isacchi, F. Zinno, G. Lucarelli (Mediterranean Institute of Hematology, Rome, Italy) 11:15 - 11:30 1018 INCREASED CD4+CD25HIGH+ REGULATORY T-CELL ARE ASSOCIATED WITH DISEASE RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) FOR CHRONIC MYELOID LEUKAEMIA (CML)
E. Nadal, J. Kaeda, J.F. Apperley, R. Lechler, F. Dazzi (Imperial College, London, United Kingdom) 11:30 - 11:45 1019 CHRONIC GVHD HAS A ROLE IN MAINTAINING REMISSIONS AFTER IMATINIB IS DISCONTINUED IN PH+ALL PATIENTS TRANSPLANTED IN CR1
B. Wassmann, H. Pfeifer, M. Stadler, M. Bornhäuser, G. Bug, M. Stelljes, R. Schwerdtfeger, N. Basara, U. Hegenbart, R. Mahlberg, D. Hoelzer, O.G. Ottmann (University Hospital Frankfurt, Frankfurt/main, Germany)

SIMULTANEOUS SESSION

10:30 - 11:45, Room M

PLATELETS AND BLEEDING DISORDERS
Chairs: T. Lisman (University Medical Center Utrecht, Utrecht, The Netherlands) P.M. Mannucci (A. Bianchi Bonomi Center, Milan, Italy)

10:30 - 10:45 1020 INCIDENCE, CLINICAL-LABORATORY FEATURES AND MANAGEMENT OF ACQUIRED VON WILLEBRAND SYNDROME AND OTHER ACQUIRED DEFECTS OF HEMOSTASIS IN A COHORT OF 240 PATIENTS WITH CHRONIC LYMPHOMYELOPROLIFERATIVE DISORDERS
A.B. Federici, P. Bucciarelli, M.T. Canciani, F. Gianniello, B. Moroni, A. Artoni, R. Bader, P.M. Mannucci (University of Milan, Milan, Italy) 10:45 - 11:00 1021 DIFFERENT ALLELIC DISTRIBUTION OF SINGLE NULCEOTIDE POLYMORPHISMS AT CODONS 10 AND 25 OF TGFB IN A GROUP OF 122 HHT ITALIAN PATIENTS AND CONTROLS
M. Martinetti, A.M. Iannone, C. Olivieri, C. Badulli, E. Sanzani, F. Pagella, L. Salvaneschi, E. Buscarini, C. Danesino (IRCCS Policlinico S. Matteo, Pavia, Italy) 11:00 - 11:15 1022 ELTROMBOPAG INCREASES PLATELETS DURING 6-WEEK TREATMENT OF ITP - RESULTS OF A RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED PHASE II STUDY
L. Stone, A. Newland, G. Cheng, M. Saleh, L. Kovaleva, J. Bussel, H. Hassani, N. Stone, A. Provan (GlaxoSmithKline, Collegeville, Pa, USA) 11:15 - 11:30 1023 GENETIC DEFECTS CAUSING TYPE 3 VON WILLEBRAND DISEASE IN HUNGARY
A. Mohl, Z. Boda, R. Jáger, H. Losonczy, A. Marosi, T. Masszi, E. Nagy, L. Nemes, T. Obser, F. Oyen, G. Radványi, Á. Schlammadinger, Z.S. Szélessy, K. Vezendy, R. Schneppenheim, I. Bodó (Semmelweis University, Budapest, Hungary) 11:30 - 11:45 1024 THE LOW MOLECULAR WEIGHT TPOR AGONIST, ELTROMBOPAG, DOES NOT PRIME PLATELET ACTIVATION IN VITRO
A. Erhardt, M. Abboud, J. Toomey, C. Erickson-Miller (GlaxoSmithKline, Collegeville, USA)

SIMULTANEOUS SESSION

10:30 - 11:45, Room B

PHILADELPHIA CHROMOSOME POSITIVE LEUKEMIAS
Chairs: O.G. Ottmann (J.W. Goethe Universität, Frankfurt, Germany) R. Foà (Università la Sapienza, Rome, Italy)

10:30 - 10:45 1025 DOMINANT ROLE OF PRE-TREATMENT BCR-ABL KINASE DOMAIN MUTATIONS IN ELDERLY DE NOVO PHILADELPHIAPOSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) PATIENTS DEVELOPING RESISTANCE TO IMATINIB-BASED TREATMENT
H. Pfeifer, B. Wassmann, A. Pavlova, T. Lange, L. Wunderle, P. Brück, M. Mueller, J. Oldenburg, A. Hochhaus, D. Hoelzer, O.G. Ottmann (Universitätsklinik Frankfurt, Frankfurt, Germany) 10:45 - 11:00 1026 RANDOMIZED COMPARISON OF IMATINIB WITH IMATINIB COMBINATION THERAPIES IN NEWLY DIAGNOSED CHRONIC MYELOGENOUS LEUKEMIA PATIENTS: DESIGN AND FIRST INTERIM ANALYSIS OF A PHASE III TRIAL
F.G. Guilhot, P. Rousselot, P. Cony-Makhoul, J.J. Sotto, B. Rio, H. Guy, H. Tilly, M. Schoenwald, J.J. Kiladjian, E. Jourdan, C.E. Bulabois, B. Christian, P. Rousselot (University Hospital, Poitiers, France) 11:00 - 11:15 1027 A FLOW-CYTOMETRIC IMMUNOBEAD ASSAY FOR THE DETECTION OF BCR-ABL FUSION ONCOPROTEIN IN PRECURSOR-B-ALL
F Weerkamp, Y.Y. Ng, K.A.J. Brouwer-de Cock, E.E.L. Koster, T. Schonewille, V.H.J. van der Velden, F.J.T. Staal, J.J.M. van Dongen (Erasmus MC, Rotterdam, The Netherlands) 11:15 - 11:30 1028 A PHASE II STUDY OF NILOTINIB (AMN107), A NOVEL INHIBITOR OF BCR-ABL, ADMINISTERED TO IMATINIB RESISTANT AND INTOLERANT PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA (CML) IN CHRONIC PHASE (CP)
P. le Coutre, N. Gattermann, S.G. O´Brien, K. Bhalla, A. Hochhaus, F. Cervantes, T. Rafferty, L. Alland, O. Ottmann, F. Giles, H. Kantarjian (Campus Virchow Charité, Berlin, Germany) 11:30 - 11:45 1029 DELETIONS OF DERIVATIVE CHROMOSOME 9 IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKAEMIA: ONLY DELETIONS THAT SPAN THE ABL/BCR BREAKPOINT ARE ASSOCIATED WITH ADVERSE PROGNOSIS
S. Kreil, K. Waghorn, M. Müller, A. Reiter, R. Hehlmann, A. Hochhaus, N.C.P. Cross (Wessex Regional Genetics Laboratory, Salisbury, United Kingdom)

SIMULTANEOUS SESSION

10:30 - 11:45, Forum

MYELODYSPLASTIC SYNDROMES
Chairs: M. Fontenay (Hôpital Cochin, Paris, France) N. Gattermann (Heinrich-Heine University, Düsseldorf, Germany)

10:30 - 10:45 1030 EXPRESSION PROFILING OF CD34+ CELLS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: INVOLVEMENT OF INTERFERON-STIMULATED GENES AND CORRELATION TO FAB SUBTYPE AND KARYOTYPE
A. Pellagatti, M. Cazzola, A. Giagounidis, L. Malcovati, M. Della Porta, S. Killick, L. Campbell, L. Wang, C. Langford, C. Fidler, D. Oscier, C. Aul, J. Wainscoat, J. Boultwood (John Radcliffe Hospital, Oxford, United Kingdom) 10:45 - 11:00 1031 LENALIDOMIDE SELECTIVELY INHIBITS IN VITRO GROWTH OF THE MALIGNANT CLONE AND UP-REGULATES SPARC IN MYELODYSPLASTIC SYNDROME (MDS) PATIENTS WITH 5Q DELETION
B. Jädersten, A. Pellagatti, A.M. Forsblom, E.K. Emanuelsson, M. Merup, J. Samuelsson, J.S. Wainscoat, J. Boultwood, E. Hellström-Lindberg (Karolinska Institutet, Stockholm, Sweden) 11:00 - 11:15 1032 CLINICAL BENEFIT FROM 2 PHASE II TRIALS EVALUATING LENALIDOMIDE (REVLIMID) IN LOWER-RISK MYELODYSPLASTIC SYNDROME PATIENTS WITH OR WITHOUT DEL 5Q CYTOGENETIC ABNORMALITIES
A.F. List, G. Dewald, J. Bennett, A. Giagounadis, A. Raza, E. Feldman, B. Powell, P. Greenberg, D. Thomas, R. Stone, C. Reeder, K. Wride, J. Patin, M. Schmidt, J.B. Zeldis, R. Knight (H. Lee Moffitt Cancer Center, Tampa, Fl, USA) 11:15 - 11:30 1033 EFFECT OF LENALIDOMIDE (CC-5013) ON GENE EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) IN MYELODYSPLASTIC SYNDROME WITH DEL(5Q) CHROMOSOME ABNORMALITY AND ITS RELEVANCE TO ANGIOGENESIS IN BONE MARROW
G. Buesche, S. Dieck, A. Giagounidis, O. Bock, L. Wilkens, B. Schlegelberger, R. Knight, J. Bennett, C. Aul, H. Kreipe (Medizinische Hochschule Hannover, Hannover, Germany) 11:30 - 11:45 1034 AN ABERRANT MRNA SPLICING PHENOTYPE IN MYELODYSPLASTIC SYNDROMES (MDS)
P. Steensma, J. Caudill, J.C. Porcher, M.E. Nelson, S.H. Kaufmann (Mayo Clinic, Rochester Mn, USA)

SIMULTANEOUS SESSION

10:30 - 11:45, Room A

ANTIBODIES IN THE TREATMENT OF CLL
Chairs: E. Montserrat (Hospital Clinic, Barcelona, Spain) M. Hallek (University of Cologne, Cologne, Germany)

10:30 - 10:45 1035 AUTOLOGOUS GRAFT VERSUS HOST DISEASE (AUTO-GVHD) AFTER AN ALEMTUZUMAB CONTAINING CONDITIONING REGIMEN AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN CLL: IMMUNOLOGICAL MECHANISMS AND POTENTIAL ANTI-LEUKAEMIA EFFECT
T. Zenz, M. Ritgen, A. Mackensen, P. Dreger, A. Kröber, T. Barth, R. Schlenk, S. Böttcher, M. Hallek, M. Kneba, H. Döhner, S. Stilgenbauer (University of Ulm, Ulm, Germany) 10:45 - 11:00 1036 PRELIMINARY RESULTS FOR THE PHASE III TRIAL OF ALEMTUZUMAB VS CHLORAMBUCIL AS FIRST-LINE TREATMENT FOR B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL)
P. Hillmen, A.S. Skotnicki, T.R. Robak, B.J. Jaksic, A.D. Dmoszynska, C.S. Sirard, J.M. Mayer (The General Infirmary at Leeds, Leeds, United Kingdom) 11:00 - 11:15 1037 CONSOLIDATION AND MAINTENANCE THERAPY WITH RITUXIMAB PROLONG DURATION OF RESPONSE BOTH WITHIN ZAP-70 POSITIVE AND NEGATIVE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
G. Del Poeta, M.I. Del Principe, P. Niscola, L. Maurillo, F. Buccisano, A. Venditti, C. Mazzone, R. Marini, A. Zucchetto, G. Suppo, F. Luciano, V. Gattei, F. Lo Coco, P. De Fabritiis, S. Amadori (Hematology, University Tor Vergata, Rome, Italy) 11:15 - 11:30 1038 LUMILIXIMAB IN COMBINATION WITH FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB (FCR) FOR PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
J. Byrd, T. Kipps, S. O'Brien, I. Flinn, A. Forero, D. Wynne, A. Molina (The Ohio State University, Columbus, USA) 11:30 - 11:45 1039 INTERIM REPORT OF THE UKCLL02 TRIAL: A PHASE II STUDY OF SUBCUTANEOUS ALEMTUZUMAB PLUS FLUDARABINE IN PATIENTS WITH FLUDARABINE REFRACTORY CLL (ON BEHALF OF THE NCRI CLL TRIALS SUB-GROUP)
H. Sayala, P. Moreton, R. Jones, A.C. Rawstron, S.J. O'Connor, P. Evans, A. Carter, C. Dearden, E. Matutes, A.R. Pettitt, B.D. Kennedy, P. Moreton, P. Hillmen (HMDS, Leeds, United Kingdom)

SIMULTANEOUS SESSION

10:30 - 11:45, Auditorium

CLINICAL STUDIES IN NON-HODGKIN'S LYMPHOMA
Chairs: U. Jäger (University of Vienna, Vienna, Austria) T. Robak (Medical University of Lodz, Lodz, Poland)

10:30 - 10:45 1040 SURVIVAL IMPACT OF THE TIME REPEATED BCL2/IGH REARRANGEMENT MEASUREMENTS IN FOLLICULAR LYMPHOMA PATIENTS TREATED WITH FRONT-LINE AUTOTRANSPLANTATION IN THE GELF-94 TRIAL BY THE GELA
F. Broussais, N. Mounier, C. Sebban, P. Brice, E. MacIntyre, P. Brice, M.H. Delfau, J.M. Cayuela, N. Brousse, C. Haioun, P. Feugier, H. Tilly, B. Coiffier, G. Salles (Centre Hospitalier lyon-Sud, Pierre-benite, France) 10:45 - 11:00 1041 LONG TERM FOLLOW UP OF 566 PATIENT WITH FOLLICULAR LYMPHOMA (FL) INCLUDED FROM 1986 TO 1995 IN THE GELF86 STUDY BEFORE RITUXIMAB AREA
P. Brice, G Salles, C. Haioun, H. Tilly, S. Le gouill, C. Foussard, C. Sebban, J. Gabarre, P. Solal-Celigny (Hôpital Saint-Louis, Paris Cedex 10, France) 11:00 - 11:15 1042 GAINS ON CHROMOSOME BAND 18Q21 PREDICT POOR OUTCOME IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A COMPARATIVE GENOMIC HYBRIDIZATION ANALYSIS WITHIN A MULTICENTRIC TRIAL (NHL-B-TRIAL)
A. Viardot, A.C. Feller, M. Kloess, M. Löffler, H.W. Bernd, G. Ott, S. Weßendorf, C. Schwaenen, M. Baudis, P. Lichter, M. Pfreundschuh, H. Döhner, L. Trümper, M. Bentz (Universitätsklinikum Ulm, Ulm, Germany) 11:15 - 11:30 1043 ASSESSMENT OF DISEASE DISSEMINATION IN GASTRIC VERSUS EXTRAGASTRIC MALT LYMPHOMA USING EXTENSIVE STAGING: A SINGLE CENTER EXPERIENCE OF 140 PATIENTS
M. Raderer, S. Woehrer, B. Streubel, M. Troch, K. Turetschek, U. Jaeger, C. Skrabs, A. Gaiger, J. Drach, A. Puespoek, M. Formanek, M. Hoffmann, W. Hauff, A. Chott (University of Vienna, Vienna, Austria) 11:30 - 11:45 1044 ANTIBIOTIC THERAPY WITH DOXYCYCLINE IS AN ACTIVE TREATMENT AGAINST OCULAR ADNEXA MALT LYMPHOMA: FINAL RESULTS OF A MULTICENTER PROSPECTIVE PHASE II TRIAL
J. M. Ferreri, M. Ponzoni, M. Guidoboni, A. Giordano Resti, L. Politi, S. Cortelazzo, F. Zallio, A. Palmas, G. P. Dognini, E. Pasini, F. Sacchetti, C. De Conciliis, C. Doglioni, R. Dolcetti (San Raffaele Scientific Institute, Milan, Italy)